Family Medicine Doctors in Bremen, IN Accepting Medicare

9 Family Medicine doctors found. Showing 1 - 9

Dr. Michael R Mcclaid, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1724 W Plymouth St, Bremen, IN 46506 Phone: 574-546-3045    Fax: 574-546-2716

Keyna Ann Martinez, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1144 W Plymouth St, Bremen, IN 46506 Phone: 574-546-5363    Fax: 574-546-2575

Frank A. Snyder, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1724 W Plymouth St, Bremen, IN 46506 Phone: 574-546-3045    Fax: 574-546-2716

David M. Rosentrater, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1724 W Plymouth St, Bremen, IN 46506 Phone: 574-546-3045    Fax: 574-546-2716

Gregory Edward Buck, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1144 W Plymouth St, Bremen, IN 46506 Phone: 574-546-5363    Fax: 574-546-2575

Dr. John Robert Larson, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1724 W Plymouth St, Bremen, IN 46506 Phone: 574-546-3649    Fax: 574-546-3952

Mrs. Laura A Both, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1144 W. Plymouth St., Bremen, IN 46506 Phone: 574-546-5363    Fax: 574-546-2575

Robert Blaine Kolbe Jr., MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1144 W Plymouth St, Bremen, IN 46506 Phone: 574-546-5363    Fax: 574-546-2575

Paul R. Gettinger, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1724 W Plymouth St, Bremen, IN 46506 Phone: 574-546-3045    Fax: 574-546-2716

News Archive

Adjuvant chemotherapy after gastric cancer procedure may reduce mortality

Patients who have gastric cancer surgery followed by chemotherapy have an associated decreased risk of death and improved disease-free survival compared to patients who have surgery alone, according to an analysis of previous studies, reported in the May 5 issue of JAMA.

FDA warns on possible fracture risk with proton pump inhibitors use

The U.S. Food and Drug Administration today warned consumers and health care professionals about a possible increased risk of fractures of the hip, wrist, and spine with high doses or long-term use of a class of medications called proton pump inhibitors. The product labeling will be changed to describe this possible increased risk.

Future lung cancer screening strategies should address equity, implementation issues, say experts

Calling the U.S. Preventive Services Task Force's newly released recommendation statement to expand eligibility for annual lung cancer screening with low-dose computed tomography a step forward, UNC Lineberger Comprehensive Cancer Center researchers say future changes should address equity and implementation issues.

FDA denies AstraZeneca Citizen Petitions on SEROQUEL labeling

AstraZeneca today announced that on March 7, 2012, the Food and Drug Administration denied Citizen Petitions requesting that the FDA withhold finally approving any generic quetiapine product with labeling that omits certain hyperglycemia warning language that the FDA required AstraZeneca to include in the labeling for SEROQUEL (quetiapine fumarate) tablets and SEROQUEL XR (quetiapine fumarate) extended-release tablets.

Read more Medical News

› Verified 7 days ago